glycine has been researched along with Dysmyelopoietic Syndromes in 24 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We previously demonstrated upregulation of c-myc, survivin, and cyclin D1 in CD34+ bone marrow mononuclear cells (BMMNCs) of patients with trisomy 8 and monosomy 7 myelodysplastic syndromes (MDS)." | 9.16 | Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. ( Groopman, J; Kwak, M; Loeliger, K; Maniar, M; Maric, I; Olnes, MJ; Pfannes, L; Scheinberg, P; Shenoy, A; Sloand, EM; Tian, X; Tucker, Z; Weinstein, B; Wilhelm, F; Yong, AS; Young, NS, 2012) |
| "We previously demonstrated upregulation of c-myc, survivin, and cyclin D1 in CD34+ bone marrow mononuclear cells (BMMNCs) of patients with trisomy 8 and monosomy 7 myelodysplastic syndromes (MDS)." | 5.16 | Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. ( Groopman, J; Kwak, M; Loeliger, K; Maniar, M; Maric, I; Olnes, MJ; Pfannes, L; Scheinberg, P; Shenoy, A; Sloand, EM; Tian, X; Tucker, Z; Weinstein, B; Wilhelm, F; Yong, AS; Young, NS, 2012) |
| "Hypomethylating agents such as 5-azacytidine or decitabine have been a major breakthrough in the treatment of patients with myelodysplastic syndromes (MDS)." | 4.87 | Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. ( Jabbour, E; Kadia, TM; Kantarjian, H, 2011) |
| " Oral roxadustat dosed thrice weekly was well tolerated." | 3.11 | Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study. ( Bartels, P; Bradley, C; Carraway, HE; Glaspy, J; Harrup, R; Henry, DH; Leong, R; Mittelman, M; Modelska, K; Saha, G; Yu, KP; Zhou, A, 2022) |
| " Mean absolute oral bioavailability ranged from 13·9% (fed) to 34·8% (fasting) in 12 patients treated at the 560 mg b." | 2.78 | Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. ( Komrokji, RS; Lancet, JE; List, AF; Maniar, M; Raza, A; Ren, C; Taft, D; Wilhelm, F, 2013) |
| "To identify the maximum-tolerated dose (MTD) and to evaluate the antileukemic activity of tosedostat (formerly CHR-2797), an orally bioavailable aminopeptidase inhibitor." | 2.75 | Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. ( Bone, E; Burnett, AK; Davies, F; Dierickx, D; Dührsen, U; Flores, N; Hooftman, L; Jenkins, C; Krug, U; Löwenberg, B; Morgan, G; Müller-Tidow, C; Ossenkoppele, GJ; Richardson, AF; Sonneveld, P; Zachée, P; Zweegman, S, 2010) |
| "The objective of this review is to evaluate the mechanism of activity, efficacy and dosing of rigosertib." | 2.49 | Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer. ( Fan, AC; Felsher, DW; O'Rourke, JJ; Praharaj, DR, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 18 (75.00) | 24.3611 |
| 2020's | 6 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Henry, DH | 1 |
| Glaspy, J | 1 |
| Harrup, R | 1 |
| Mittelman, M | 1 |
| Zhou, A | 1 |
| Carraway, HE | 1 |
| Bradley, C | 1 |
| Saha, G | 1 |
| Modelska, K | 1 |
| Bartels, P | 1 |
| Leong, R | 1 |
| Yu, KP | 1 |
| Patnaik, MM | 1 |
| Santini, V | 2 |
| Navada, SC | 3 |
| Garcia-Manero, G | 3 |
| OdchimarReissig, R | 1 |
| Pemmaraju, N | 1 |
| Alvarado, Y | 1 |
| Ohanian, MN | 1 |
| John, RB | 1 |
| Demakos, EP | 2 |
| Zbyszewski, PS | 3 |
| Maniar, M | 4 |
| Woodman, RC | 1 |
| Fruchtman, SM | 3 |
| Silverman, LR | 6 |
| Platzbecker, U | 4 |
| Lee, S | 1 |
| Desai, P | 1 |
| Edirisinghe, B | 1 |
| Pianello, S | 1 |
| Curcio, T | 1 |
| Samuel, M | 1 |
| Ritchie, EK | 1 |
| Roboz, GJ | 2 |
| Parisi, S | 1 |
| Finelli, C | 1 |
| Fazio, A | 1 |
| De Stefano, A | 1 |
| Mongiorgi, S | 1 |
| Ratti, S | 1 |
| Cappellini, A | 1 |
| Billi, AM | 1 |
| Cocco, L | 1 |
| Follo, MY | 1 |
| Manzoli, L | 1 |
| Jost, M | 1 |
| Chen, Y | 1 |
| Gilbert, LA | 1 |
| Horlbeck, MA | 1 |
| Krenning, L | 1 |
| Menchon, G | 1 |
| Rai, A | 1 |
| Cho, MY | 1 |
| Stern, JJ | 1 |
| Prota, AE | 1 |
| Kampmann, M | 1 |
| Akhmanova, A | 1 |
| Steinmetz, MO | 1 |
| Tanenbaum, ME | 1 |
| Weissman, JS | 1 |
| Odchimar-Reissig, R | 1 |
| Petrone, ME | 1 |
| Holland, JF | 2 |
| Nazha, A | 1 |
| Sekeres, MA | 2 |
| Komrokji, R | 1 |
| Steensma, DP | 2 |
| Kantarjian, H | 3 |
| Roboz, G | 1 |
| Fenaux, P | 2 |
| Prebet, T | 1 |
| Azarnia, N | 2 |
| Balaian, E | 1 |
| Weidner, H | 1 |
| Wobus, M | 1 |
| Baschant, U | 1 |
| Jacobi, A | 1 |
| Mies, A | 1 |
| Bornhäuser, M | 1 |
| Guck, J | 1 |
| Hofbauer, LC | 1 |
| Rauner, M | 1 |
| Komrokji, RS | 1 |
| Raza, A | 2 |
| Lancet, JE | 1 |
| Ren, C | 1 |
| Taft, D | 1 |
| Wilhelm, F | 4 |
| List, AF | 2 |
| Fan, AC | 2 |
| O'Rourke, JJ | 1 |
| Praharaj, DR | 1 |
| Felsher, DW | 2 |
| Greenberg, P | 2 |
| Olnes, MJ | 2 |
| Reddy, P | 1 |
| Xu, F | 1 |
| He, Q | 1 |
| Li, X | 1 |
| Chang, CK | 1 |
| Wu, LY | 1 |
| Zhang, Z | 1 |
| Liu, L | 1 |
| Shi, WH | 1 |
| Zhu, Y | 1 |
| Zhao, YS | 1 |
| Gu, SC | 1 |
| Fei, CM | 1 |
| Guo, J | 1 |
| Wu, D | 1 |
| Zhou, L | 1 |
| Hyoda, T | 1 |
| Tsujioka, T | 1 |
| Nakahara, T | 1 |
| Suemori, S | 1 |
| Okamoto, S | 1 |
| Kataoka, M | 1 |
| Tohyama, K | 1 |
| Mawad, R | 1 |
| Becker, PS | 1 |
| Hendrie, P | 1 |
| Scott, B | 1 |
| Wood, BL | 1 |
| Dean, C | 1 |
| Sandhu, V | 1 |
| Deeg, HJ | 1 |
| Walter, R | 1 |
| Wang, L | 1 |
| Myint, H | 1 |
| Singer, JW | 1 |
| Estey, E | 1 |
| Pagel, JM | 1 |
| Al-Kali, A | 1 |
| Baer, MR | 1 |
| Gaidano, G | 1 |
| Scott, BL | 1 |
| Kambhampati, S | 1 |
| Kreuzer, KA | 1 |
| Godley, LA | 1 |
| Atallah, E | 1 |
| Collins, R | 1 |
| Jabbour, E | 2 |
| Wilhelm, FE | 1 |
| Löwenberg, B | 1 |
| Morgan, G | 1 |
| Ossenkoppele, GJ | 1 |
| Burnett, AK | 1 |
| Zachée, P | 1 |
| Dührsen, U | 1 |
| Dierickx, D | 1 |
| Müller-Tidow, C | 1 |
| Sonneveld, P | 1 |
| Krug, U | 1 |
| Bone, E | 1 |
| Flores, N | 1 |
| Richardson, AF | 1 |
| Hooftman, L | 1 |
| Jenkins, C | 1 |
| Zweegman, S | 1 |
| Davies, F | 1 |
| Seetharam, M | 1 |
| Tran, M | 1 |
| Xu, L | 1 |
| Renschler, JP | 1 |
| Sridhar, K | 1 |
| Greenberg, PL | 1 |
| Kadia, TM | 1 |
| Shenoy, A | 1 |
| Weinstein, B | 1 |
| Pfannes, L | 1 |
| Loeliger, K | 1 |
| Tucker, Z | 1 |
| Tian, X | 1 |
| Kwak, M | 1 |
| Yong, AS | 1 |
| Maric, I | 1 |
| Scheinberg, P | 1 |
| Groopman, J | 1 |
| Young, NS | 1 |
| Sloand, EM | 1 |
| Mundle, SD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory Myelodysplastic Syndrome With Ring Sideroblasts (MDS-RS): A Prospective Randomized Controlled Study[NCT06006949] | Phase 4 | 62 participants (Anticipated) | Interventional | 2023-08-31 | Not yet recruiting | ||
| A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients With Lower Risk Myelodysplastic Syndrome (MDS) With Low Red Blood Cell (RBC) Transfusion Burden (L[NCT03263091] | Phase 3 | 140 participants (Actual) | Interventional | 2017-09-07 | Terminated (stopped due to Study did not meet its primary efficacy endpoint.) | ||
| A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia[NCT01926587] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Atients With Myelodysplastic Syndromes (MDS) After Failure of Hypomethylating Agent-Based Therapy[NCT02452346] | Phase 2 | 12 participants (Actual) | Interventional | 2015-03-20 | Completed | ||
| Phase I Dose Escalation Study of ON 01910.Na With Increasing Duration of an Initial 3-Day Continuous Infusion in Patients With Refractory Leukemia or MDS[NCT00854646] | Phase 1 | 22 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine[NCT01928537] | Phase 3 | 67 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| A Phase 2, Single-Arm Study To Assess The Efficacy and Safety Of 72-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Every Other Week in Myelodysplastic Syndrome Patients With Trisomy 8 or Classified as Intermediate-1, 2 or High Risk[NCT00906334] | Phase 2 | 14 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent[NCT02562443] | Phase 3 | 372 participants (Actual) | Interventional | 2015-12-02 | Terminated (stopped due to Top line analysis indicated that the study had failed to achieve its primary endpoint.) | ||
| Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine[NCT01241500] | Phase 3 | 299 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| A Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Intermediate-1, Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System[NCT01904682] | Phase 2 | 45 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification[NCT01584531] | Phase 2 | 82 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| A Phase 1/2, Single-Arm Study To Assess The Efficacy and Safety Of 72-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Every Other Week in Patients With Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)[NCT00854945] | Phase 1/Phase 2 | 36 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Phase 1 Study to Assess Tolerability, PK and PD Activity of ON 01910.Na Administered Orally as Escalating Single and Multiple Doses Twice a Day up to 14 Days of a 21-Day Cycle in Patients With Myelodysplastic Syndrome[NCT01048619] | Phase 1 | 36 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| A Phase I-II Study to Evaluate the Safety, Tolerability and Anti-Disease Activity of the Aminopeptidase Inhibitor, CHR-2797, in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia or Multiple Myeloma[NCT00689000] | Phase 1/Phase 2 | 57 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With RAEB-1 AND RAEB-2 Myelodysplastic Syndrome (MDS) and AML With Trisomy 8[NCT00533416] | Phase 1 | 14 participants (Actual) | Interventional | 2007-09-14 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Survival following treatment to the date of death, assessed up to a period of 3-4 years. (NCT02452346)
Timeframe: from start of treatment until death, assessed up to a period of 3-4 years.
| Intervention | months (Median) |
|---|---|
| All Patients | 15.9 |
6 reviews available for glycine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Clinical and Molecular Insights in Erythropoiesis Regulation of Signal Transduction Pathways in Myelodysplastic Syndromes and β-Thalassemia.
Topics: Animals; beta-Thalassemia; Cell Differentiation; Cell Proliferation; Clinical Trials as Topic; Eryth | 2021 |
Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.
Topics: Antineoplastic Agents; Biomarkers; Glycine; Humans; Myelodysplastic Syndromes; Nanotechnology; Neopl | 2013 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
Topics: Adenine Nucleotides; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibod | 2011 |
New therapeutics for myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Bone Marrow; Chromosomes, Human, Pair 5; Glycine; Humans; Hydrox | 2012 |
11 trials available for glycine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study.
Topics: Aged; Anemia; Double-Blind Method; Female; Glycine; Humans; Isoquinolines; Male; Middle Aged; Myelod | 2022 |
Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study.
Topics: Aged; Anemia; Double-Blind Method; Female; Glycine; Humans; Isoquinolines; Male; Middle Aged; Myelod | 2022 |
Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study.
Topics: Aged; Anemia; Double-Blind Method; Female; Glycine; Humans; Isoquinolines; Male; Middle Aged; Myelod | 2022 |
Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study.
Topics: Aged; Anemia; Double-Blind Method; Female; Glycine; Humans; Isoquinolines; Male; Middle Aged; Myelod | 2022 |
Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Female; Glycine; Humans; Leukemia, Myelogenous, Chronic | 2020 |
Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy.
Topics: Azacitidine; DNA Methylation; Glycine; Humans; Hydroxamic Acids; Myelodysplastic Syndromes; Treatmen | 2021 |
A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Dose-Response Relationship, Dru | 2018 |
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.
Topics: Antineoplastic Agents; Azacitidine; Decitabine; Drug Resistance, Neoplasm; Glycine; Humans; Kaplan-M | 2017 |
Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Biological Availability; Capsules; Disease Progressio | 2013 |
Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; De | 2016 |
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Topics: Aged; Azacitidine; Decitabine; Disease-Free Survival; DNA Methylation; Drug Administration Schedule; | 2016 |
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Topics: Aged; Azacitidine; Decitabine; Disease-Free Survival; DNA Methylation; Drug Administration Schedule; | 2016 |
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Topics: Aged; Azacitidine; Decitabine; Disease-Free Survival; DNA Methylation; Drug Administration Schedule; | 2016 |
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Topics: Aged; Azacitidine; Decitabine; Disease-Free Survival; DNA Methylation; Drug Administration Schedule; | 2016 |
Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.
Topics: Adult; Aged; Aged, 80 and over; Aminopeptidases; Female; Glycine; Humans; Hydroxamic Acids; Leukemia | 2010 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Bone Marrow Cells; Chromosomes, Human, P | 2012 |
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Bone Marrow Cells; Chromosomes, Human, P | 2012 |
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Bone Marrow Cells; Chromosomes, Human, P | 2012 |
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Bone Marrow Cells; Chromosomes, Human, P | 2012 |
7 other studies available for glycine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Targeting ineffective hematopoiesis in myelodysplastic syndromes.
Topics: Aged; Anemia; Blood Transfusion; Disease Management; Female; Glycine; Hematinics; Hematopoiesis; Hum | 2022 |
New Approaches for Anemia in MDS.
Topics: Activin Receptors, Type II; Anemia; Female; Glycine; Humans; Immunoglobulin Fc Fragments; Isoquinoli | 2020 |
Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent.
Topics: Antineoplastic Agents; Colchicine; CRISPR-Cas Systems; Drug Resistance, Neoplasm; Gene Expression Re | 2017 |
Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.
Topics: Animals; Glycine; Hematopoiesis; Hematopoietic Stem Cells; Mesenchymal Stem Cells; Mice; Mice, Trans | 2019 |
Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Cell Line; Female; G2 Phase Cell C | 2014 |
Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest.
Topics: Antineoplastic Agents; Apoptosis; Aurora Kinase A; Cell Line, Tumor; Cell Proliferation; DNA Damage; | 2015 |
Targeting cyclin D1 for high risk myelodysplastic syndromes.
Topics: Cyclin D1; Female; Glycine; Humans; Male; Molecular Targeted Therapy; Myelodysplastic Syndromes; Sul | 2012 |